Product Name: Frk (494-500) pY497
Product Number: PE-04AMN95
Size: | 200 µg | | Price: | 47.00 |
| 1 mg | | $US | 94.00 |
| 5 mg | | | 206.00 |
Peptide Name: Frk (494-500) pY497
Product Use: Services as a blocking peptide for use with the Frk-pY497 rabbit polyclonal antibody (Cat. No.: AB-PK642) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the C-terminus of the kinase. One of the two major in vivo phosphorylation sites in Frk. By analogy with other Src family kinases, this is likely inhibitory to the phosphotransferase activity of Frk.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: DSS-pY-SDA
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: βAla-Cys
Peptide Modifications Other: Phosphorylated
Peptide Molecular Mass Calculated: 996.9 Da
Peptide Purity Percent after Synthesis and Purification: >95
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: Frk - pY497 phosphosite-specific antibody (Cat. No.: AB-PK642) Scientific Background: Frk is a protein-tyrosine kinase of the TK group and Src family that is found in the nucleus.. It is involved in positive regulation of PTEN by increasing its stability and preventing degradation and negative regulation of cell proliferation. It may also have functions during G1 and S phase in the nucleus to suppress growth. Frk may be a tumour suppressor protein (TSP). Cancer-related mutations in human tumours point to a loss of function of the protein kinase. nsertional mutagenesis studies in mice support a role for this protein kinase in mouse cancer oncogenesis.